Charles C. Wykoff, MD PhD
Show Description +
Charles C. Wykoff, MD, PhD, performs one of the first commercial procedures using encapsulated cell-based gene therapy Encelto (revakinagene taroretcel-lwey) for a patient with idiopathic Macular Telangiectasia Type 2 (MacTel).
Posted: 8/12/2025
Charles C. Wykoff, MD PhD
Charles C. Wykoff, MD, PhD, performs one of the first commercial procedures using encapsulated cell-based gene therapy Encelto (revakinagene taroretcel-lwey) for a patient with idiopathic Macular Telangiectasia Type 2 (MacTel).
Posted: 8/12/2025
Please log in to leave a comment.